Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2− metastatic breast cancer
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag182 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Oncologist, online erschienen am 07.05.2026. Verfasst von Adam Brufsky und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, U…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
Background
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is), palbociclib, ribociclib, and abemaciclib, are approved for HR+/HER2− metastatic breast cancer (mBC). This real-world study evaluated treatment durations and subsequent treatments of patients with HR+/HER2− mBC who received CDK4/6is plus aromatase inhibitor (AI) in the United States.
Methods
Adult patients with HR+/HER2− mBC who initiated first-line (1L) CDK4/6is plus AI (February 2015-July 2024) were selected from the US-based Flatiron Health Research database. Stabilized inverse probability of treatment weighting (sIPTW) was conducted. Kaplan−Meier analyses estimated treatment durations.
Results
Of 11 557 patients, 8109, 2006, and 1442 received 1L palbociclib, ribociclib, and abemaciclib, respectively. After sIPTW, treatment duration was longer for the palbociclib group (median: 20.7 months) than the ribociclib (18.3 months) and abemaciclib (17.1 months) groups (ribociclib vs palbociclib: hazard ratio [HR] = 1.12 [95% confidence interval (CI), 1.05-1.20], P = .0008; abemaciclib vs palbociclib: HR = 1.13 [95% CI, 1.05-1.22], P = .0012). Treatment durations were similar between the ribociclib and abemaciclib groups (HR = 1.01 [95% CI, 0.92-1.11], P = .8280). Twelve-month treatment discontinuation rates were higher among patients initiating ribociclib or abemaciclib, at 39.4% and 41.1%, respectively, than among patients initiating palbociclib (33.3%). In the analysis of patients who initiated palbociclib, ribociclib, or abemaciclib from 2017 onward, 49.9%, 37.3%, and 39.4%, respectively, received subsequent treatments; CDK4/6i-containing regimens accounted for 42.3%, 54.1%, and 55.7%, respectively; notably, more patients initially treated with ribociclib or abemaciclib transitioned to palbociclib than those who switched oppositely.
Conclusions
Treatment durations, discontinuation rates, and subsequent treatments differ between CDK4/6is for HR+/HER2− mBC in US routine clinical practice. Clinical Trial Registration Number NCT06495164
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, United States.
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
- US Oncology Medical Affairs, Pfizer Inc., New York, NY 10001, United States.
- Global Biometrics & Data Management, Pfizer Inc., New York, NY 10001, United States.
- Research Oncology, Flatiron Health Inc., New York, NY 10013, United States.
- Research Sciences, Flatiron Health Inc., New York, NY 10013, United States.
ORCID-Profile: Adam Brufsky, Giuseppe Curigliano
Förderung
- Pfizer Inc
Zitieren
APA
Brufsky, A., Layman, R. M., Liu, X., Li, B., McRoy, L., Cohen, A., Estevez, M., Cottu, P., Thill, M., Curigliano, G., & Rugo, H. S. (2026). Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2− metastatic breast cancer. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag182
Vancouver
Brufsky A, Layman RM, Liu X, Li B, McRoy L, Cohen A, et al. Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2− metastatic breast cancer. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag182
BibTeX
@article{Brufsky2026,
author = {Brufsky, Adam and Layman, Rachel M and Liu, Xianchen and Li, Benjamin and McRoy, Lynn and Cohen, Aaron and Estevez, Melissa and Cottu, Paul and Thill, Marc and Curigliano, Giuseppe and Rugo, Hope S},
title = {Real-world treatment durations, subsequent treatments, and switching of CDK4/6 inhibitors among patients with HR+/HER2− metastatic breast cancer},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag182}
}
EUVIMED